Pink Sheet Daily
August 11, 2013
Executive SummaryAs Beijing municipal authorities take on the latest bribery allegations against a foreign drug maker, this time Sanofi, experts say China is beginning to get a handle on its long-nagging issue of high prices.
As Beijing municipal authorities take on the latest bribery allegations against a foreign drug maker, this time Sanofi, experts say China is beginning to get a handle on its long-nagging issue of high prices. Beijing investigators were quick to establish a joint investigation into a whistleblower's allegations Sanofi paid a total of $274,048 to 503 doctors at 79 city hospitals. The China clampdown on drug prices can be traced back to at least a year ago when officials counted 31 imported treatments selling at twice the prices charged in the U.K., followed by several other studies that led to a series of investigations of multinational drug makers, beginning with GlaxoSmithKline. One analyst said the government is concerned the high prices are interfering with health-care access at a time it is spending billions to expand access to all parts of the country.
Executive SummaryAs Beijing municipal authorities take on the latest bribery allegations against a foreign drug maker, this time Sanofi, experts say China is beginning to get a handle on its long-nagging issue of high prices.
As Beijing municipal authorities take on the latest bribery allegations against a foreign drug maker, this time Sanofi, experts say China is beginning to get a handle on its long-nagging issue of high prices. Beijing investigators were quick to establish a joint investigation into a whistleblower's allegations Sanofi paid a total of $274,048 to 503 doctors at 79 city hospitals. The China clampdown on drug prices can be traced back to at least a year ago when officials counted 31 imported treatments selling at twice the prices charged in the U.K., followed by several other studies that led to a series of investigations of multinational drug makers, beginning with GlaxoSmithKline. One analyst said the government is concerned the high prices are interfering with health-care access at a time it is spending billions to expand access to all parts of the country.